ONCOGENI LTD

Active London

Activities of head offices

0 employees website.com
Activities of head offices
O

ONCOGENI LTD

Activities of head offices

Founded 29 May 2019 Active London, England 0 employees website.com
Activities of head offices
Accounts Submitted 20 Aug 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 16 Apr 2025 Next due 29 Apr 2026 8 days remaining
Net assets £-20K £5K 2024 year on year
Total assets £931 £207K 2024 year on year
Total Liabilities £21K £202K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

85 Great Portland Street First Floor London W1W 7LT England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for ONCOGENI LTD (12021845), an active company based in London, England. Incorporated 29 May 2019. Activities of head offices. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

£931.00

Decreased by £200.00k (-100%)

Net Assets

-£19.80k

Decreased by £5.21k (-36%)

Total Liabilities

£20.73k

Decreased by £202.09k (-91%)

Turnover

N/A

Employees

N/A

Debt Ratio

2227%

Increased by 2120 (+1981%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

2 Allotments 6,892,226 Shares £42320.01m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
22 Feb 20216,708,226£7k£0.001
22 Jan 2020184,000£42320.00m£230k

Officers

Officers

1 active 2 resigned
Status
Ajan Trevor ReginaldDirectorBritishUnited Kingdom5429 May 2019Active

Shareholders

Shareholders (1)

Roquefort Therapeutics Plc
100.0%

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
20 Oct 2025OfficersTermination of Trevor Ajan Reginald as director on 2025-07-01
20 Aug 2025AccountsAnnual accounts made up to 2024-12-31
16 Apr 2025Confirmation StatementConfirmation statement made on 2025-04-15 with no updates
28 Oct 2024AccountsAnnual accounts made up to 2023-05-31
11 Oct 2024AccountsAnnual accounts made up to 2023-12-31
20 Oct 2025 Officers

Termination of Trevor Ajan Reginald as director on 2025-07-01

20 Aug 2025 Accounts

Annual accounts made up to 2024-12-31

16 Apr 2025 Confirmation Statement

Confirmation statement made on 2025-04-15 with no updates

28 Oct 2024 Accounts

Annual accounts made up to 2023-05-31

11 Oct 2024 Accounts

Annual accounts made up to 2023-12-31

Recent Activity

Latest Activity

Termination of Trevor Ajan Reginald as director on 2025-07-01

6 months ago on 20 Oct 2025

Annual accounts made up to 2024-12-31

8 months ago on 20 Aug 2025

Confirmation statement made on 2025-04-15 with no updates

1 years ago on 16 Apr 2025

Annual accounts made up to 2023-05-31

1 years ago on 28 Oct 2024

Annual accounts made up to 2023-12-31

1 years ago on 11 Oct 2024